Components of Adolescent Behavioural Interventions With Eating Disorder Outcomes: Systematic Review With Intervention Mapping
- PMID: 41367220
- PMCID: PMC12690354
- DOI: 10.1111/ijpo.70074
Components of Adolescent Behavioural Interventions With Eating Disorder Outcomes: Systematic Review With Intervention Mapping
Abstract
Objective: To understand delivery features and intervention strategies of adolescent weight management interventions which may influence eating disorder risk.
Methods: Systematic searches in four databases and two trial registries to identify randomised controlled trials in adolescents with overweight/obesity measuring eating disorder risk pre- and post-intervention. Delivery features and intervention strategies were coded from published descriptions using a project-specific codebook, validated by trial investigators and narratively synthesised.
Results: Of 11 860 records screened, 23 trials, with 54 intervention arms, were included in the analysis. Most interventions focused on weight loss and maintenance (54%) and were informed by a cognitive behavioural framework (43%). Interventions commonly targeted an individual with a support person (70%). Median intervention duration was 26 weeks, with weekly (35%) or staged (e.g., weekly, then monthly) visit (41%) frequency. Interventions had a mean (SD) of 30 (16.1) intervention strategies. Most included healthy eating education (89%), physical activity education (89%) and problem-solving barriers to dietary change (80%). Few included mental health strategies (17%). Interventions included 'dietary prescription' (65%), and 78% promoted 'healthful/helpful eating behaviours'.
Conclusion: Weight management interventions are complex and vary in delivery approach and strategies used to change behaviors. Characterising interventions is a critical first step to understanding how weight management interventions' influence eating disorder risk.
Keywords: behaviour change techniques; disordered eating; obesity; obesity treatment; overweight.
© 2025 The Author(s). Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Conflict of interest statement
N.B.L., R.K., I.R.J., S.P., H.M., A.L.S, K.E.H., C.B., S.P.G., S.M., D.N., S.J.P., K.S., K.C., G.D., A.M.G., F.Q., M.R., J.Y., M.K.B., M.P.B., K.N.B., K.E.D., D.M.E., L.H.E., A.B.G., E.J., M.C.L.‐P., T.N., W.L.P., R.I.S., M.T.‐K., A.V.E., B.J.J., H.J. declare no conflicts of interest. A.L.A. is on the Scientific Advisory Board for WW and chairs a Trial Steering Committee for Menwell Ltd. L.A.B. is immediate Past‐President (2022–2024) of the World Obesity Federation, an honorary, unpaid position. She has received honoraria for speaking in forums organised by Novo Nordisk (NN) in relation to management of adolescent obesity (funds directed to research cost centre). L.A.B. is the Australian lead of the study—ACTION Teens: sponsored by NN (multi‐country on‐line study of attitudes towards and perceptions of obesity held by adolescents living with obesity, their parents and health care professionals). L.A.B. has received honoraria (funds directed to hospital research cost centre) for being a member of the Lilly Weight Management Advisory Board. A.J.H. has received payment for advice given to Slimming World (UK). M.K.P. has received travel and consulting fees for speaking and advisory boards from Novo Nordisk, Eli Lilly, Johnson and Johnson Medical Pty Ltd, Takeda Pharmaceuticals and iNova Pharmaceuticals. He was on the guideline development committee for the National Eating Disorder Collaboration ‘Management of eating disorders for people with higher weight: clinical practice guideline (2022)’ and is Vice President of the Australia and New Zealand Obesity Society (ANZOS). A.S. owns 50% of the shares in Zuman International Pty Ltd, which receives royalties and other payments for educational resources and services in adult weight management and research methodology. F.A.N.H. reports serving on the Obesity Society's Finance Committee, consulting fees from WW, an honorarium for speaking from the American Academy of Pediatrics, institutional support to travel and membership on the Obesity Action Coalition's Membership and Access to Care Committees, outside the scope of the submitted work. R.A.J. is an employee and shareholder of WeightWatchers International (WW). T.K.K. has received professional fees from Novo Nordisk, Nutrisystem, Emerald Lake Safety, Roman Health Ventures and Boehringer Ingelheim. M.I.C. is an employee and shareholder of WW International Inc. A.L.D. has an honorary, unpaid position at Nutrition Society of Australia as Honorary Secretary and Director of the Board from 2024. H.F.S. previously received salary from Novo Nordisk unrelated to the present work. Y.S.D. received a one‐time payment from NovoNordisk for creating information materials about eating disorders for health care professionals. Y.S.D. is part of the steering group of the E‐BATTLE Obesity trial a placebo‐controlled RCT testing semaglutide in the treatment of severe obesity in adolescents (starting in 2025). Medications and placebo‐medications are provided by Novo Nordisk but not funding for the study. A.P.V. has received consulting fees from Rhythm Pharmaceuticals and Soleno Pharmaceuticals. J.A.Y. reports unrelated grant funds to NICHD supporting his clinical research from Soleno Therapeutics, Rhythm Pharmaceuticals and Hikma Pharmaceuticals and materials from Versanis Bio to support mouse studies.
Figures
References
-
- Al‐shoaibi A. A. A., Lavender J. M., Kim S. J., et al., “Association of Body Mass Index With Progression From Binge‐Eating Behavior Into Binge‐Eating Disorder Among Adolescents in the United States: A Prospective Analysis of Pooled Data,” Appetite 200 (2024): 107419, 10.1016/j.appet.2024.107419. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
